TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06938867: Phase 1b/2a Randomized Double-blind Study to Investigate Safety Tolerability PK PD Preliminary Efficacy of Oral Administration of SNIPR001 in Patients With Hematologic Malignancy S

Sponsor: SNIPR Biome Aps. · Phase: PHASE1/PHASE2 · Area: INFECTIOUS_VACCINE · Target Enrollment: 66 pts

Competing Trials Overlap

8 Active Trials

Excess Burn Exposure

$1,099,560

Rescue Site Savings

+$724,710

Unlock Full NCT06938867 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06938867 Rescue Dossier →